Biotech · Public company · New York, NY, US

Lexeo Therapeutics, Inc.

Ticker LXEO · SEC CIK 0001907108

Track this companyFree. Adds Lexeo Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials87 recruiting or active

Pipeline programs7From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline7

Study of LX2006 Gene Therapy in Friedreich Ataxia CardiomyopathyPHASE2 · RECRUITING · started Jun 25, 2026ClinicalTrials.gov NCT07721025 · fetched Nov 12, 2026
Clinical Course Of Disease In Participants With FA-CMRECRUITING · started Sep 30, 2025ClinicalTrials.gov NCT06865482 · fetched Nov 12, 2026
Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic VariantENROLLING_BY_INVITATION · started Aug 29, 2025ClinicalTrials.gov NCT07050160 · fetched Nov 12, 2026
Gene Therapy for ACM Due to a PKP2 Pathogenic VariantPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 29, 2024ClinicalTrials.gov NCT06109181 · fetched Nov 12, 2026
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACMRECRUITING · started Jan 23, 2024ClinicalTrials.gov NCT06976606 · fetched Nov 12, 2026
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's DiseasePHASE1 · ACTIVE_NOT_RECRUITING · started May 8, 2023ClinicalTrials.gov NCT05400330 · fetched Nov 12, 2026
Gene Therapy for Cardiomyopathy Associated With Friedreich's AtaxiaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 24, 2022ClinicalTrials.gov NCT05445323 · fetched Nov 12, 2026
Gene Therapy for APOE4 Homozygote of Alzheimer's DiseasePHASE1_PHASE2 · COMPLETED · started Nov 6, 2019ClinicalTrials.gov NCT03634007 · fetched Nov 12, 2026